Antimicrobial

KATALYST LAUNCHES FOURTH-GENERATION FITNESS SUIT, AGAIN RAISING THE STANDARD FOR ELECTRO MUSCLE STIMULATION (EMS) TRAINING

New Gen4 Suit Offers Enhanced Design, Optimal Fit, and Superior Durability LAS VEGAS, Nov. 13, 2024 /PRNewswire/ -- Katalyst, the leader…

1 month ago

Cosmos Health Issues Letter to Shareholders

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

1 month ago

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical…

1 month ago

Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Trial reaches dosing milestone, with 20 of the 30 total patients dosedAll patients dosed met the primary endpoints of the…

2 months ago

Biotia Gets First-Ever NY State Regulatory Approval for a Urine Infectious Disease Test Powered by Genomics and AI

NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Biotia, a leading innovator in genomic-based infectious disease diagnostics, announced a major milestone…

2 months ago

Oracle Health Data Intelligence Updates Help Healthcare Organizations Improve Care Quality, Operational Efficiency, and Financial Performance

AI-powered clinical intelligence prioritizes patient outreach based on likelihood of successful intervention to improve patient health and reduce costly emergency…

2 months ago

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 /…

2 months ago

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a…

2 months ago

Kane Biotech Announces Exclusive Distribution Agreement With XSONX

WINNIPEG, Manitoba, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that…

2 months ago

Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024

ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine…

2 months ago